Clinical Features, Cytogenetics, Immunophenotype, and Gene Rearrangements of Patients With a t(4;11)(q21p14-15)
| Patient No. . | Sex/ Age (yr) . | WBC (×109/L) . | Diagnosis . | Survival (mo) . | Karyotype . | Immunophenotype . | Gene Rearrangement . | Reference . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/21 | 423 | ALL L1 | 43 | 46,XY,t(4;11)(q21p15) +2mar (presentation) 48,XY,t(4;11),−7, −7,−9,−9,11p+, 17p+,−20,−21, −21 +9 mar (final relapse) | CD2+, CD3+ (30%), CD4−, CD5+, CD7+, CD8−, CD10+, CD11b (14%), CD14−, CD19−, CD20−, CD33+ (34%), CD34+, CD71+, HLA-DR+ | IgH (R) TCRγ (R) | 7 This report |
| 2 | F/25 | 1.8 | ALL L1 | 1 | 46,XX,t(4;11)(q21p14-15),del(12)(p13), +del(13)(q12q14) | CD2+ (13%), CD3−, CD4−, CD5+ (13%), CD7+, CD8−, CD10+ (14%), CD13+ (5%), CD14−, CD19−, CD33+ (18%), CD34+ (5%) | IgH (G) TCRγ (R) | This report |
| 3 | M/49 | 169 | ALL L2 | 14 | 46,XY,t(4;11)(q21p15), del(5)(q13q31) | CD2−, CD4−, CD5+, CD7+, CD8−, CD10+ (9%), CD19−, CD34+ | IgH (G) TCRγ (R) | This report |
| 4 | M/14 | 1.4 | ALL L2 | 1 | 46,XY,t(4;11)(q21p14), 12p-/46,XY, t(4;11)(q21p14) | CD2−, CD5+, CD10−, CD15+, pan-T+, TdT+ | ND | 21 |
| 5 | M/40 | 127 | ALL | 21 | 46,XY,t(4;11)(q21p15) | T (surface markers not reported) | ND | 22 |
| 6 | F/6 | 49 | ALL L2 | 25+ | 46,XX,t(4;11) (q21p14-15) | CD2+, CD5−, CD7+, CD10−, CD11b+, CD13+, CD14−, CD15−, CD19−, CD20−, CD22−, CD33+, CD36−, HLA-DR+, TdT+ | ND | 23 |
| Patient No. . | Sex/ Age (yr) . | WBC (×109/L) . | Diagnosis . | Survival (mo) . | Karyotype . | Immunophenotype . | Gene Rearrangement . | Reference . |
|---|---|---|---|---|---|---|---|---|
| 1 | M/21 | 423 | ALL L1 | 43 | 46,XY,t(4;11)(q21p15) +2mar (presentation) 48,XY,t(4;11),−7, −7,−9,−9,11p+, 17p+,−20,−21, −21 +9 mar (final relapse) | CD2+, CD3+ (30%), CD4−, CD5+, CD7+, CD8−, CD10+, CD11b (14%), CD14−, CD19−, CD20−, CD33+ (34%), CD34+, CD71+, HLA-DR+ | IgH (R) TCRγ (R) | 7 This report |
| 2 | F/25 | 1.8 | ALL L1 | 1 | 46,XX,t(4;11)(q21p14-15),del(12)(p13), +del(13)(q12q14) | CD2+ (13%), CD3−, CD4−, CD5+ (13%), CD7+, CD8−, CD10+ (14%), CD13+ (5%), CD14−, CD19−, CD33+ (18%), CD34+ (5%) | IgH (G) TCRγ (R) | This report |
| 3 | M/49 | 169 | ALL L2 | 14 | 46,XY,t(4;11)(q21p15), del(5)(q13q31) | CD2−, CD4−, CD5+, CD7+, CD8−, CD10+ (9%), CD19−, CD34+ | IgH (G) TCRγ (R) | This report |
| 4 | M/14 | 1.4 | ALL L2 | 1 | 46,XY,t(4;11)(q21p14), 12p-/46,XY, t(4;11)(q21p14) | CD2−, CD5+, CD10−, CD15+, pan-T+, TdT+ | ND | 21 |
| 5 | M/40 | 127 | ALL | 21 | 46,XY,t(4;11)(q21p15) | T (surface markers not reported) | ND | 22 |
| 6 | F/6 | 49 | ALL L2 | 25+ | 46,XX,t(4;11) (q21p14-15) | CD2+, CD5−, CD7+, CD10−, CD11b+, CD13+, CD14−, CD15−, CD19−, CD20−, CD22−, CD33+, CD36−, HLA-DR+, TdT+ | ND | 23 |
Details of the 3 patients reported in this study (no. 1, 2, and 3) and 3 patients from the literature (no. 4, 5, and 6) are presented. All features except for survival are at presentation. The comparatively long survival of patient no. 1 is at least in part due to the patient having undergone 2 allogeneic transplantations. The survival time of patient no. 5 is unknown but is at least 25 months. Where surface markers are positive in less than 50% of cells, the values are indicated in parentheses. Rearrangements of the heavy chain of Ig (IgH) and of the T-cell receptor γ gene (TCRγ) are indicated as G (germline, no rearrangement) or R (rearranged).
Abbreviations: WBC, white blood cell count; ND, not determined.